Prescribing information

 

   

Watch MS experts in your area introduce KESIMPTA’s mode of action, dosing and administration, and clinical efficacy and safety.

Meeting date: 7th July 2021

 

ASCLEPIOS KESIMPTA: What will this mean for your patients?

Dr Ian Pomeroy discusses the role of B cell therapy in MS and introduces KESIMPTA’s mode of action, posology, and efficacy and safety profiles. Karen Vernon, MS Nurse Specialist, discusses the impact of COVID-19 on MS services and the new ways of working that have emerged as a result.

Meeting date: 21st July 2021

 

An expert’s perspective in MS – ‘To B or not to B’

Watch UK MS experts Dr Eli Silber, Dr Waqar Rashid, Dr Matt Craner, Dr Wallace Brownlee and Consultant Nurse Noreen Barker discuss the launch of KESIMPTA and key topics of interest in MS including the COVID-19 pandemic, the importance of B-cells in MS and share their experience of setting up a KESIMPTA patient pathway in the UK.

 

Meeting date: 1st September 2021

 

KESIMPTA: An alternative way to manage your relapsing-remitting multiple sclerosis (RRMS) patients across Scotland

In this wide-ranging meeting, Dr Katy Murray asks, “To B or not to B, and what will KESIMPTA data and protocol mean for your patients?” Also, Dr Niall MacDougall looks at MS in Scotland from the perspective of past, present, and future. Whilst the subject of early intervention is discussed by Dr Martin Duddy, and Dr Barry Singer looks at real-world evidence for KESIMPTA.

 

Prescribing information for KESIMPTA▼ (ofatumumab) and adverse event reporting details can be found here.
Prescribing information for GILENYA▼ (fingolimod) and adverse event reporting details can be found here.

These meetings were organised and funded by Novartis Pharmaceuticals UK Ltd. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.

MS, multiple sclerosis.

Rate this content: 
Average: 5 (1 vote)
UK | January 2022 | 172789
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]